May 2 |
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
May 1 |
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
|
Apr 22 |
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
|
Apr 5 |
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
Apr 3 |
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
|
Mar 18 |
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
|
Mar 12 |
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
|
Mar 11 |
KalVista Pharmaceuticals GAAP EPS of -$0.84 misses by $0.07
|
Mar 11 |
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
|
Mar 8 |
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
|